Joshua M. Bauml

Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (2)

Purpose: Investigator-initiated trials (IIT) may address important biological and clinical questions that may not be prioritized by pharmaceutical sponsors. However, little is known about the process by which IIT proposals are evaluated and activated. Experimental Design: We performed a retrospective study of IIT concepts submitted through the Academic Thoracic Oncology Medical Investigators Consortium, which comprises 13 institutions in the United States and Canada, from consortium inception in 2014 to 2024. We compared approved and disapproved concepts using χ 2 tests, Fisher exact tests, and Wilcoxon rank-sum tests. Results: Among 68 presented IIT concepts, 60 (88%) received consortium approval a median of 30 days (IQR, 31–59 days) after submission. Concepts submitted by junior faculty were more likely to be approved than those from full professors ( P = 0.003). Of the 60 concepts subsequently submitted to pharmaceutical sponsors, 15 (25%) were approved, 43 (72%) were disapproved, and 2 (3%) remain under review. The median time between concept submission to a sponsor and the sponsor’s decision was 61 days (IQR, 31–183 days). Concepts with shorter projected durations were more likely to be approved by the pharmaceutical sponsor ( P = 0.05). For sponsor-approved IIT concepts, the median overall time from initial submission to trial activation was 18 months. Conclusions: Only a small proportion of proposed investigator-initiated cancer clinical trials are successfully activated following a prolonged development process. Given the importance of IITs in addressing real-world, practical questions and the growing professional challenges facing clinical research physician faculty, further attention to IIT development facilitators and barriers is warranted.

Year:

2025

Background We performed an integrated biomarker evaluation in pembrolizumab‐treated patients with R/M HNSCC enrolled in KEYNOTE‐012 or KEYNOTE‐055. The relationship between biomarkers and HPV status was explored. Methods We evaluated PD‐L1 (combined positive score [CPS]), TMB, T‐cell‐inflamed gene expression profile (Tcell inf GEP), and HPV status. Associations between biomarkers were evaluated by logistic regression (ORR) and Cox regression (PFS, OS). Results Two hundred and fifty‐seven patients (KEYNOTE‐012, n = 106; KEYNOTE‐055, n = 151) had TMB data available; of these, 254 had PD‐L1 and 236 had Tcell inf GEP. TMB, PD‐L1, and Tcell inf GEP were each significantly associated with ORR ( p < 0.01). Kaplan–Meier curves at prespecified cutoffs generally showed PFS and OS separation in the anticipated direction for these biomarkers, except for OS and TMB. TMB did not correlate with PD‐L1 or Tcell inf GEP (Spearman ρ = −0.03 and ρ = −0.13, respectively); PD‐L1 and Tcell inf GEP were moderately correlated (Spearman ρ = 0.47). In multivariate models, TMB, PD‐L1, and Tcell inf GEP were each independently predictive for ORR ( p < 0.001). ORR was higher in patients with high versus low levels of biomarkers when dichotomized using prespecified cutoffs; patients with higher versus lower levels of TMB and PD‐L1 or TMB and Tcell inf GEP had the highest ORRs. Within HPV subgroups, higher versus lower distributions of biomarkers (PD‐L1, TMB, and Tcell inf GEP) were associated with response. HPV detection by p16‐immunohistochemistry and WES showed good concordance (81%); results were generally similar by HPV status, regardless of the detection method. Conclusions TMB and the inflammatory biomarkers PD‐L1 and Tcell inf GEP, assessed alone or together, may be useful for characterizing clinical response to pembrolizumab in R/M HNSCC.

Year:

2022

Collaborators (5)

David Gerber

Professor of Internal Medicine (Hematology-Oncology) and Clinical Sciences

University of Texas Southwestern Medical Center

UNITED STATES
View details

Stephen Liu

Associate Professor

Georgetown University School of Medicine

UNITED STATES
View details

Song Zhang

-

UNITED STATES
View details

Wade T. Iams

-

UNITED STATES
View details

Tejas Patil

Assistant Professor

University of Colorado School of Medicine

UNITED STATES
View details